Merz Therapeutics
June 16, 2025
Company Presentation
Brain Health
153B
Merz Therapeutics is a specialty neurology biopharma focused on movement disorders, rare and ophan neurological diseases and chronic pain seeking in-licensing and acquisition opportunities. Areas of highest interest include Multiple Sclerosis, Parkinson’s Disease and other diseases characterized by motor dysfunction such as dystonia, spasticity, blepharospasms;, Ataxia Rare and orphan neurological disorders including hereditary neuropathies and neurodegenerative diseases, ideally with movement disorder aspects Migraine and chronic pain, e.g. neuropathic pain We look forward to discuss strategic partnerships/in-licensing/M&A for patent protected commercial and development stage assets in Phase 2 or later.
Company HQ City:
Raleigh
Company HQ State:
NC
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
Xeomin
CEO
Stefan Konig
Development Phase of Lead Product
Multiple Products in Market
What is your next catalyst (value inflection) update?
Actively seeking in-license and acquisition opportunities
Website
https://merztherapeutics.com/
Primary Speaker
)
)
){kind=logo}
){kind=logo}
){kind=logo}